Clinical trials: Healthy Subjects;Overweight or Obesity
Overweight or Obesity; Type 2 Diabetes
A Study of Single and Multiple Doses HRS9531 Tablets in Healthy Subjects
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of HRS9531tablets in healthy subjects.
- Trial name
- NCT06435676
- Testing
- HRS9531
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Healthy Participants
A Study to Assess the Relative Bioavailability of Different Subcutaneous Formulations ofAZD6234
This study in healthy volunteers aims to compare blood levels and side effects after administration of different formulations of AZD6234.
- Trial name
- NCT07220954
- Testing
- AZD6234 Formulation 1, AZD6234 Formulation 2 (low concentration), AZD6234 Formulation 2 (high concentration)
- Where
- United Kingdom
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Overweight, Obesity
A Study to See How Safe a New Medicine (NNC6989-0001) is in Healthy People Living With Overweight or Obesity
This study is testing a new medicine, NNC6989-0001, to test it is safe and tolerable for healthy people living with overweight or obesity.
- Trial name
- NCT07437079
- Testing
- NNC6989-0001
- Where
- United States
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Obese or Overweight Healthy Volunteers
Clinical Study to Assess the Safety and Efficacy of ACV Moringa Effervescent Tablet Intake on Weight Management in Overweight and Class I Obese Study Participants
A Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Single-Centre, Clinical Study to Evaluate the Safety and Efficacy of Intake of ACV Moringa on the Degree of Weight Change in Overweight and Class I Obese Study Participants
- Trial name
- NCT07098624
- Testing
- ACV Moringa Effervescent Tablets 4.3 g
- Volunteers
- 66 people
- Sponsor
- NovoBliss Research Pvt Ltd
Obesity &Amp; Overweight
This is an Open-label, Non-randomized Study to Assess the Pharmacokinetics (PK) of VCT220 in Healthy Volunteers When Administered With Rifampin or Itraconazole
This is a single-center, open-label, single-arm, fixed-sequence Phase I study in healthy participants to evaluate the effect of multiple doses of rifampin or itraconazole on the pharmacokinetics (PK) of VCT220 and its metabolite…
- Trial name
- NCT07056842
- Testing
- Rifampin + VCT220, Itraconazole + VCT220
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Vincentage Pharma Co., Ltd
Healthy Subjects, Obesity
Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes
The phase 1 portion of the study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TLC-6740 after single- and multiple-ascending doses in healthy subjects.
- Conditions
- Healthy Subjects, Obesity, Type 2 Diabetes
- Trial name
- NCT05822544
- Testing
- TLC-6740 Oral Solution, TLC-6740 Tablet, Drug Metabolizing Enzyme
- Where
- 4 sites in New Zealand
- Volunteers
- 564 people, healthy volunteers welcome
- Sponsor
- OrsoBio, Inc
Healthy Subjects
A Study to Evaluate the Safety, Tolerability, PK/PD of HEC-007 Injection in Healthy and Overweight/Obese Subjects
This trial adopts a single-center, randomized, double-blind, placebo-controlled, dose-escalation design to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HEC-007 Injection after single-dose…
- Trial name
- NCT07102251
- Testing
- HEC-007 injection
- Where
- China
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Obesity
Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects
The main purpose of this study is measure the effect of VI-0521 on kidney function. Specifically, glomerular filtration rate (GFR) will be measured at baseline, after 4 weeks of study treatment, and after an additional 4 weeks of…
- Trial name
- NCT02229214
- Testing
- Qsymia
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- VIVUS LLC
Overweight or Obesity
A Study of SYH2092 Injection in Healthy Participants
To evaluate the safety and tolerability of SYH2092 Injection in healthy participants
- Trial name
- NCT07776041
- Testing
- SYH2092 Injection
- Where
- Australia
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Overweight (BMI > 25), Obese But Otherwise Healthy Participants
Pistachio Snacking and Metabolic Flexibility
The purpose of this study is to evaluate the effects of pistachio snacking on metabolic flexibility (at rest, during exercise, and in post-exercise recovery) in healthy overweight and obese adults.
- Conditions
- Overweight (BMI > 25), Obese But Otherwise Healthy Participants, Overweight or Obese, Obese Patients (BMI ≥ 30 kg/m²)
- Trial name
- NCT07340125
- Testing
- Pistachio
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of South Carolina
Overweight , Obesity
Phase 1 Clinical Study of MWN110 Injection in Healthy Participants and Overweight or Obese Participants
This study is a multicenter, randomized, double-blind, placebo-controlled, single and multiple ascending-dose phase 1 clinical trial aimed at evaluating the safety, tolerability, PK, PD, and immunogenicity of MWN110 Injection in…
- Trial name
- NCT07779980
- Testing
- MWN110
- Where
- China
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Bone Diseases, Obesity
Stereophotogrammetry of the Torso in Healthy Individuals and Patients With Scoliosis, Chest Wall Deformations, or Obesity
Background: Stereophotogrammetry (SP) uses four sets of digital cameras to generate a three-dimensional computer image. Unlike other types of evaluations which require radiation, SP only uses computer images to learn more about…
- Conditions
- Bone Diseases, Obesity, Healthy Volunteers
- Trial name
- NCT01352949
- Where
- United States
- Volunteers
- 199 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Type 2 Diabetes Mellitus
A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-5823 in Overweight or Obese Participants Who Are Healthy or Have Type 2 Diabetes Mellitus (MK-5823-002)
The purpose of this study is to assess the multiple rising dose safety/tolerability and pharmacokinetics of MK-5823 in overweight/obese participants who are healthy and overweight/obese participants with Type 2 diabetes mellitus…
- Trial name
- NCT01614782
- Testing
- MK-5823
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Healthy, Obese
A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight
The main purpose of this study is to see how much of orforglipron (study drug) gets into the bloodstream and how long it takes the body to get rid of it when given as capsules compared to tablets in healthy overweight and obese…
- Conditions
- Healthy, Obese, Overweight, Obesity
- Trial name
- NCT06440980
- Testing
- Orforglipron
- Where
- 7 sites in United States
- Volunteers
- 533 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Overweight, Obesity
A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or Obesity
This study is open to adults with overweight or obesity who are otherwise healthy. People can join the study if they have a body mass index of 27 to 39.9 kg/m2 and a body weight over 70 kg.
- Trial name
- NCT06564441
- Testing
- Survodutide, Bupropion, Caffeine
- Where
- Belgium
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
End Stage Renal Disease, Renal Impairment
A Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics (PK) of Ribupatide
The primary objective of the study is to estimate the PK parameters of ribupatide in participants with severe renal impairment or end-stage kidney disease (ESKD) after a single dose of ribupatide subcutaneous (SC) injection…
- Conditions
- End Stage Renal Disease, Renal Impairment, Obesity, Overweight
- Trial name
- NCT07793929
- Testing
- Ribupatide
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Kailera
Healthy Volunteers (Diabetes Mellitus, Type 2)
A Research Study of a New Medicine NNC0519-0130 in Healthy People, People With High Body Weight and People With Type 2 Diabetes.
NNC0519-0130 is a new medicine which may possibly help participants with type 2 diabetes, as it is expected to lower elevated sugar levels in the blood. The medicine may also lower the appetite.
- Trial name
- NCT05363774
- Testing
- NNC0519-0130
- Where
- 3 sites in Denmark, Germany
- Volunteers
- 161 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Safety, Healthy Subjects
A Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Overweight/Obese Subjects of Japanese or Chinese Descent
This is a phase I, randomized, blinded study to evaluate the safety and pharmacokinetics of MEDI0382 following single dose administration to overweight/obese subjects of Japanese or Chinese descent
- Trial name
- NCT03385369
- Testing
- MEDI0382
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC